Noradrenaline Infusion Versus Phenylephrine Infusion in Improving Serum Lactate Level in HIPEC
Effect of Noradrenaline Infusuion Versus Phenyephrine Infusion in Improving Tissue Perfusion in HIPEC
1 other identifier
interventional
30
1 country
1
Brief Summary
ABG PARAMETERS ARE CHANGED DURING HIPEC, WE TRIED TO FIND COMPARISON BETWEEN NORADRENALINE AND PHENYLEPHRINE IN OPTIMIZING ABG PARAMETERS THAT REFLECTS ORGAN PERFUSIONS ESPECIALLY SERUM LACTATE
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2019
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 19, 2019
CompletedFirst Posted
Study publicly available on registry
October 30, 2019
CompletedStudy Start
First participant enrolled
November 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2023
CompletedMay 29, 2024
May 1, 2024
4 years
October 19, 2019
May 27, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
SERUM LACTATE IN ABG
LANDMARK FOR TISSUE AND ORGAN PERFUSION
IMMEDIATELY POSTOPERATIVELY
Study Arms (2)
NORADRENALIN
ACTIVE COMPARATORNORADRENALINE INFUSION
PHENYLEPHRINE
ACTIVE COMPARATORPHENYLEPHRINE INFUSION
Interventions
DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
Eligibility Criteria
You may qualify if:
- CANCER PATIENTS ENROLLED FOR HIPEC
You may not qualify if:
- DRUG SENSITIVITY
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Suez Canal University
Ismailia, 41511, Egypt
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical professor
Study Record Dates
First Submitted
October 19, 2019
First Posted
October 30, 2019
Study Start
November 1, 2019
Primary Completion
October 30, 2023
Study Completion
December 30, 2023
Last Updated
May 29, 2024
Record last verified: 2024-05
Data Sharing
- IPD Sharing
- Will not share